Eli Lilly's recently launched oral obesity medication, Foundayo, has seen a robust initial uptake according to early prescription data. The drug, which offers a convenient pill alternative to existing injectable weight-loss therapies, is generating significant early interest from healthcare providers.
Analysts tracking the launch reported that approximately 1,390 prescriptions were written for Foundayo in just two days. This early momentum suggests strong physician and patient demand for an effective oral option in the rapidly expanding obesity treatment market, though specific efficacy and safety data from this early commercial phase were not detailed in the source.